Literature DB >> 33875644

JAC1 suppresses proliferation of breast cancer through the JWA/p38/SMURF1/HER2 signaling.

Yanlin Ren1,2,3, Dongyin Chen4, Zurong Zhai1,2, Junjie Chen1,2, Aiping Li1,2, Yan Liang2,5, Jianwei Zhou6,7.   

Abstract

The overexpression of HER2 is associated with a malignant proliferation of breast cancer. In this study, we developed a non-cytotoxic JWA gene activating compound 1 (JAC1) to inhibit the proliferation of HER2-positive breast cancer cells in vitro and in vivo experimental models. JAC1 increased the ubiquitination of HER2 at the K716 site through the E3 ubiquitin ligase SMURF1 which was due to the decreased expression of NEDD4, the E3 ubiquitin ligase of SMURF1. In conclusion, JAC1 suppresses the proliferation of HER2-positive breast cancer cells through the JWA triggered HER2 ubiquitination signaling. JAC1 may serve as a potential therapeutic agent for HER2-positive breast cancer.

Entities:  

Year:  2021        PMID: 33875644     DOI: 10.1038/s41420-021-00426-y

Source DB:  PubMed          Journal:  Cell Death Discov        ISSN: 2058-7716


  39 in total

Review 1.  Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Authors:  Noam Pondé; Mariana Brandão; Georges El-Hachem; Emilie Werbrouck; Martine Piccart
Journal:  Cancer Treat Rev       Date:  2018-05-02       Impact factor: 12.111

Review 2.  Breast cancer statistics, 2013.

Authors:  Carol DeSantis; Jiemin Ma; Leah Bryan; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-10-01       Impact factor: 508.702

3.  Early diagnosis and detection of breast cancer.

Authors:  Marina Milosevic; Dragan Jankovic; Aleksandar Milenkovic; Dragan Stojanov
Journal:  Technol Health Care       Date:  2018       Impact factor: 1.285

Review 4.  HER2-positive breast cancer.

Authors:  Sibylle Loibl; Luca Gianni
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

5.  Cancer survival in Africa, Asia, and Central America: a population-based study.

Authors:  Rengaswamy Sankaranarayanan; Rajaraman Swaminathan; Hermann Brenner; Kexin Chen; Kee Seng Chia; Jian Guo Chen; Stephen C K Law; Yoon-Ok Ahn; Yong Bing Xiang; Balakrishna B Yeole; Hai Rim Shin; Viswanathan Shanta; Ze Hong Woo; Nimit Martin; Yupa Sumitsawan; Hutcha Sriplung; Adolfo Ortiz Barboza; Sultan Eser; Bhagwan M Nene; Krittika Suwanrungruang; Padmavathiamma Jayalekshmi; Rajesh Dikshit; Henry Wabinga; Divina B Esteban; Adriano Laudico; Yasmin Bhurgri; Ebrima Bah; Nasser Al-Hamdan
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

Authors:  Andrew M Wardley; Xavier Pivot; Flavia Morales-Vasquez; Luis M Zetina; Maria de Fátima Dias Gaui; Douglas Otero Reyes; Jacek Jassem; Claire Barton; Peter Button; Veronica Hersberger; Antonio Antón Torres
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

Review 8.  Key steps for effective breast cancer prevention.

Authors:  Kara L Britt; Jack Cuzick; Kelly-Anne Phillips
Journal:  Nat Rev Cancer       Date:  2020-06-11       Impact factor: 60.716

Review 9.  Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

Authors:  Jiani Wang; Binghe Xu
Journal:  Signal Transduct Target Ther       Date:  2019-09-13

Review 10.  Breast Cancer Treatment: A Review.

Authors:  Adrienne G Waks; Eric P Winer
Journal:  JAMA       Date:  2019-01-22       Impact factor: 56.272

View more
  5 in total

1.  JAC4 Protects from X-ray Radiation-Induced Intestinal Injury by JWA-Mediated Anti-Oxidation/Inflammation Signaling.

Authors:  Yan Zhou; Jingwen Liu; Xiong Li; Luman Wang; Lirong Hu; Aiping Li; Jianwei Zhou
Journal:  Antioxidants (Basel)       Date:  2022-05-27

2.  Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2.

Authors:  Zundong Liu; Xiaolin Sang; Min Wang; Yichao Liu; Jiao Liu; Xuefei Wang; Pixu Liu; Hailing Cheng
Journal:  Oncogene       Date:  2021-09-23       Impact factor: 9.867

3.  JAC1 targets YY1 mediated JWA/p38 MAPK signaling to inhibit proliferation and induce apoptosis in TNBC.

Authors:  Zurong Zhai; Yanlin Ren; Chuanjun Shu; Dongyin Chen; Xia Liu; Yan Liang; Aiping Li; Jianwei Zhou
Journal:  Cell Death Discov       Date:  2022-04-05

4.  TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer.

Authors:  Yayun Gu; Huanyao Gao; Huan Zhang; August John; Xiujuan Zhu; Suganti Shivaram; Jia Yu; Richard M Weinshilboum; Liewei Wang
Journal:  Oncogene       Date:  2022-07-21       Impact factor: 8.756

Review 5.  Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery.

Authors:  Kun Ding; Xia Liu; Luman Wang; Lu Zou; Xuqian Jiang; Aiping Li; Jianwei Zhou
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.